Elimination of lymphatic filariasis: do we have the drugs to complete the job?
Identifieur interne : 002919 ( PubMed/Corpus ); précédent : 002918; suivant : 002920Elimination of lymphatic filariasis: do we have the drugs to complete the job?
Auteurs : Moses J. Bockarie ; Rinki M. DebSource :
- Current opinion in infectious diseases [ 1473-6527 ] ; 2010.
English descriptors
- KwdEn :
- Africa, Animals, Antiparasitic Agents (pharmacology), Antiparasitic Agents (therapeutic use), Drug Administration Schedule, Drug Therapy, Combination, Elephantiasis, Filarial (complications), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (transmission), Filaricides (administration & dosage), Filaricides (pharmacology), Filaricides (therapeutic use), Global Health, Humans, Insect Vectors (parasitology), Loiasis (complications), Program Evaluation, Time Factors, Treatment Outcome, World Health Organization.
- MESH :
- chemical , administration & dosage : Filaricides.
- chemical , pharmacology : Antiparasitic Agents, Filaricides.
- chemical , therapeutic use : Antiparasitic Agents, Filaricides.
- geographic : Africa.
- complications : Elephantiasis, Filarial, Loiasis.
- drug therapy : Elephantiasis, Filarial.
- parasitology : Insect Vectors.
- transmission : Elephantiasis, Filarial.
- Animals, Drug Administration Schedule, Drug Therapy, Combination, Global Health, Humans, Program Evaluation, Time Factors, Treatment Outcome, World Health Organization.
Abstract
Lymphatic filariasis is targeted for elimination globally through mass drug administration (MDA) with diethylcarbamazine or ivermectin monotherapy, or either drug in combination with albendazole. However, many countries that have implemented MDA annually for over 5 years are yet to interrupt transmission. This review describes the current drugs used in MDA and highlights the challenges facing the WHO Global Programme to Eliminate Lymphatic Filariasis (GPELF).
DOI: 10.1097/QCO.0b013e32833fdee5
PubMed: 20847694
Links to Exploration step
pubmed:20847694Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Elimination of lymphatic filariasis: do we have the drugs to complete the job?</title><author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J" last="Bockarie">Moses J. Bockarie</name><affiliation><nlm:affiliation>Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, UK. moses.bockarie@liv.ac.uk</nlm:affiliation></affiliation></author><author><name sortKey="Deb, Rinki M" sort="Deb, Rinki M" uniqKey="Deb R" first="Rinki M" last="Deb">Rinki M. Deb</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20847694</idno><idno type="pmid">20847694</idno><idno type="doi">10.1097/QCO.0b013e32833fdee5</idno><idno type="wicri:Area/PubMed/Corpus">002919</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002919</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Elimination of lymphatic filariasis: do we have the drugs to complete the job?</title><author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J" last="Bockarie">Moses J. Bockarie</name><affiliation><nlm:affiliation>Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, UK. moses.bockarie@liv.ac.uk</nlm:affiliation></affiliation></author><author><name sortKey="Deb, Rinki M" sort="Deb, Rinki M" uniqKey="Deb R" first="Rinki M" last="Deb">Rinki M. Deb</name></author></analytic><series><title level="j">Current opinion in infectious diseases</title><idno type="eISSN">1473-6527</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Africa</term><term>Animals</term><term>Antiparasitic Agents (pharmacology)</term><term>Antiparasitic Agents (therapeutic use)</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (complications)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (transmission)</term><term>Filaricides (administration & dosage)</term><term>Filaricides (pharmacology)</term><term>Filaricides (therapeutic use)</term><term>Global Health</term><term>Humans</term><term>Insect Vectors (parasitology)</term><term>Loiasis (complications)</term><term>Program Evaluation</term><term>Time Factors</term><term>Treatment Outcome</term><term>World Health Organization</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparasitic Agents</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparasitic Agents</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Africa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Loiasis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Insect Vectors</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Global Health</term><term>Humans</term><term>Program Evaluation</term><term>Time Factors</term><term>Treatment Outcome</term><term>World Health Organization</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphatic filariasis is targeted for elimination globally through mass drug administration (MDA) with diethylcarbamazine or ivermectin monotherapy, or either drug in combination with albendazole. However, many countries that have implemented MDA annually for over 5 years are yet to interrupt transmission. This review describes the current drugs used in MDA and highlights the challenges facing the WHO Global Programme to Eliminate Lymphatic Filariasis (GPELF).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20847694</PMID><DateCreated><Year>2010</Year><Month>10</Month><Day>29</Day></DateCreated><DateCompleted><Year>2011</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6527</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current opinion in infectious diseases</Title><ISOAbbreviation>Curr. Opin. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Elimination of lymphatic filariasis: do we have the drugs to complete the job?</ArticleTitle><Pagination><MedlinePgn>617-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QCO.0b013e32833fdee5</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Lymphatic filariasis is targeted for elimination globally through mass drug administration (MDA) with diethylcarbamazine or ivermectin monotherapy, or either drug in combination with albendazole. However, many countries that have implemented MDA annually for over 5 years are yet to interrupt transmission. This review describes the current drugs used in MDA and highlights the challenges facing the WHO Global Programme to Eliminate Lymphatic Filariasis (GPELF).</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Current drugs used for MDA implementation by national elimination programmes only temporarily clear microfilariae without killing all adult worms. Generally, reports of serious adverse events associated with MDA for lymphatic filariasis using current drugs are uncommon. However, in areas in Africa where lymphatic filariasis co-exists with Loa loa, progressive neurologic decline and encephalopathy within a few days of taking ivermectin have caused great concern. Doxycycline, which is effective at eliminating the Wolbachia symbiont from the lymphatic filariasis parasite, is showing promise as an alternative treatment option for areas where lymphatic filariasis is co-endemic with Loa loa.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Alternative and effective MDA regimens and strategies will be needed if the GPELF is to achieve the goals of global elimination of lymphatic filariasis by 2020. Further research to test new drug regimens (including single high doses of albendazole) or alternative treatment regimens (including biannual treatment schedules) may also be necessary. A new drug, moxidectin, which is currently under development for use against onchocerciasis, may be effective against lymphatic filariasis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bockarie</LastName><ForeName>Moses J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, UK. moses.bockarie@liv.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deb</LastName><ForeName>Rinki M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Infect Dis</MedlineTA><NlmUniqueID>8809878</NlmUniqueID><ISSNLinking>0951-7375</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000977">Antiparasitic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000349" MajorTopicYN="N" Type="Geographic">Africa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000977" MajorTopicYN="N">Antiparasitic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007303" MajorTopicYN="N">Insect Vectors</DescriptorName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008118" MajorTopicYN="N">Loiasis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015397" MajorTopicYN="N">Program Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20847694</ArticleId><ArticleId IdType="doi">10.1097/QCO.0b013e32833fdee5</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002919 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002919 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:20847694
|texte= Elimination of lymphatic filariasis: do we have the drugs to complete the job?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20847694" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |